Clinical Trial Update: Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients [Phase 2]

View source ↗

Summary

Phase 2 adaptive-dose finding trial assessing NIM811 with standard of care in relapsed hepatitis C genotype-1 patients; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Hepatitis Genotype-1 Relapse

Drugs mentioned

• NIM811 (NIM-811)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Hepatitis C Genotype-1 Relapse | Phase 2 | Status: COMPLETED